What Krystal Biotech (KRYS)'s VYJUVEK Gene Therapy Momentum Means For Shareholders

Krystal Biotech’s VYJUVEK gene therapy for dystrophic epidermolysis bullosa has already delivered strong commercial traction, generating high revenue and robust gross margins in chronic use. The therapy’s specialized manufacturing process, treatment experience, and recurring revenue model have created a meaningful competitive moat, even as European pricing negotiations and emerging rivals introduce new uncertainties. Next, we’ll explore how VYJUVEK’s high-margin, recurring revenue profile...